Fresh2 Group Past Earnings Performance
Past criteria checks 0/6
Fresh2 Group's earnings have been declining at an average annual rate of -7.6%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 10.4% per year.
Key information
-7.6%
Earnings growth rate
26.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -10.4% |
| Return on equity | -123.2% |
| Net Margin | -803.4% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
AnPac Bio announces plan to implement ADS ratio change
Oct 18AnPac Bio-Medical Science announces management changes
Oct 03AnPac Bio-Medical Science signed equity investment totaling $3.67M with new investor Group
Sep 27AnPac Bio appoints Yuyang Cui as co-chief executive officer
Aug 05AnPac Bio stock soars 15% after securing first disease treatment patent in U.S.
Jun 18AnPac Bio wins new US patent for multi-cancer detection
Feb 01AnPac Bio (ANPC) skyrockets 136% on advancement in detecting pre-cancer diseases
Dec 14Industry Analysts Just Upgraded Their AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) Revenue Forecasts By 55%
Dec 11
AnPac Bio-Medical rallies on Q3 record test volume; FY20 revenue estimated at +100%
Nov 25AnPac Bio's Chinese company secures COVID-19 nucleic acid test certification; shares +33%
Nov 02Revenue & Expenses BreakdownBeta
How Fresh2 Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 17 | -136 | 116 | 12 |
| 31 Mar 23 | 11 | -110 | 92 | 9 |
| 31 Dec 22 | 12 | -102 | 83 | 10 |
| 30 Sep 22 | 11 | -61 | 58 | 8 |
| 30 Jun 22 | 9 | -70 | 58 | 11 |
| 31 Mar 22 | 18 | -104 | 92 | 15 |
| 31 Dec 21 | 18 | -119 | 102 | 16 |
| 30 Sep 21 | 25 | -98 | 99 | 12 |
| 30 Jun 21 | 26 | -81 | 92 | 10 |
| 31 Mar 21 | 22 | -88 | 94 | 12 |
| 31 Dec 20 | 21 | -80 | 94 | 12 |
| 30 Sep 20 | 12 | -112 | 103 | 14 |
| 30 Jun 20 | 11 | -122 | 107 | 13 |
| 31 Mar 20 | 10 | -105 | 91 | 11 |
| 31 Dec 19 | 11 | -101 | 83 | 10 |
| 30 Sep 19 | 12 | -69 | 64 | 9 |
| 31 Dec 18 | 10 | -42 | 38 | 10 |
| 31 Dec 17 | 6 | -39 | 31 | 11 |
Quality Earnings: FRES is currently unprofitable.
Growing Profit Margin: FRES is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FRES is unprofitable, and losses have increased over the past 5 years at a rate of 7.6% per year.
Accelerating Growth: Unable to compare FRES's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FRES is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: FRES has a negative Return on Equity (-123.16%), as it is currently unprofitable.